Shionogi
Maria Ruiz Azpiroz has a solid work experience in the field of market access. Maria started their career at Centro de Biología Molecular Severo Ochoa, CBMSO in 2017 as a research intern. Maria then moved on to Center for Molecular Biology Severo Ochoa (CBMSO) in 2018, where they also worked as a research intern for a short period of time. In 2019, they joined Centro de Biología Molecular Severo Ochoa, CBMSO again, this time as a research intern.
In 2020, Maria joined Shionogi Inc. as a Market Access Trainee. Maria later became a Market Access Intern from March 2021 to June 2022, and finally transitioned to their current role as a Market Access Specialist in June 2022.
Maria Ruiz Azpiroz completed their education in a chronological order. Maria began by earning a Bachelor of Science (BSc) degree in Biochemistry and Molecular Biology from Universidad Autónoma de Madrid, which they attended from 2015 to 2019. In 2017, they had a brief academic experience at Boston University, where they also pursued Biochemistry and Molecular Biology.
Following this, Maria pursued a Master's Degree in Management of Pharma-Biotech Companies from the University of Navarra, where they studied from 2019 to 2020. Later, they joined Universidad Carlos III de Madrid to pursue a Master's degree in Evaluación Sanitaria y Acceso al Mercado (Fármaco - Economía), which they obtained in 2022.
Additionally, Maria holds two certifications: a Certificate of Proficiency in English (CPE) from Cambridge Assessment English and a Diplôme approfondi de langue française - DALF C2 from the Centre international d'études pédagogiques (CIEP). However, the specific obtained months and years for these certifications were not provided.
This person is not in any offices
Shionogi
10 followers
Shionogi Inc. is the U.S. subsidiary of Shionogi & Co., Ltd., a 140-year-old global pharmaceutical company with headquarters in Osaka, Japan. In the U.S., Shionogi Inc. leverages their science-based heritage to develop and commercialize pharmaceutical products to treat unmet medical needs in our core areas of infectious diseases and pain, as well as other areas of high medical need, including chronic liver disease.